The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Methods of manufacturing inositol-stabilized arginine-silicate (“ASI”) complexes with reduced or eliminated clumping and with increased solubility.

Methods of manufacturing inositol-stabilized arginine-silicate (“ASI”) complexes with reduced or eliminated clumping and with increased solubility.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

A polyguanidine biocidal compound miscible with an anionic surfactant. PHMG and PHMB are modified with a variety of different carboxylic acids. Carboxyl groups are added to the ends of the linear polyguanidine chain giving them the structure and properties of an amphoteric surfactant. The modified polyguanidine is now miscible with anionic surfactants while retaining the original bactericidal properties. In this way, it can be compounded with modified polyguanidine and anionic surfactant to produce a product with both sterilization and decontamination properties that is usable in daily use products, and industrial and agricultural fields. A method of manufacturing a polyguanidine biocidal compound is also provided.

A polyguanidine biocidal compound miscible with an anionic surfactant. PHMG and PHMB are modified with a variety of different carboxylic acids. Carboxyl groups are added to the ends of the linear polyguanidine chain giving them the structure and properties of an amphoteric surfactant. The modified polyguanidine is now miscible with anionic surfactants while retaining the original bactericidal properties. In this way, it can be compounded with modified polyguanidine and anionic surfactant to produce a product with both sterilization and decontamination properties that is usable in daily use products, and industrial and agricultural fields. A method of manufacturing a polyguanidine biocidal compound is also provided.

The present disclosure relates to methods for producing polymers and resins, the method including a first reacting of at least a first diamine with a first carbonate-containing compound and a second carbonate-containing compound to produce at least one of the polymer or the resin, where the first reacting is according to

##STR00001##

each of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 include at least one of a hydrogen atom, a methyl group, a saturated hydrocarbon chain, and/or an unsaturated hydrocarbon chain, and R comprises at least one of a carbon atom, a saturated hydrocarbon chain, and/or an unsaturated hydrocarbon chain.